Ligbas, Rosemarie H.
HRN: 14-15-41 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/21/2023
CO-AMOXICLAV 625MG (TAB)
06/21/2023
06/28/2023
PO
625mg
BID
Laceration, Fracture
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes